Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
76.65 USD | -2.44% |
|
-1.34% | +6.47% |
09/07 | RBC Raises Price Target on Intra-Cellular Therapies to $107 From $103, Keeps Outperform Rating | MT |
01/07 | Intra-Cellular Therapies, Inc.(NasdaqGS:ITCI) added to Russell 1000 Dynamic Index | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.47% | 8.3B | |
+7.46% | 100B | |
+11.97% | 42.34B | |
-11.32% | 32.76B | |
+79.34% | 29.46B | |
-12.28% | 16.31B | |
+3.58% | 14.39B | |
-1.90% | 12.23B | |
+178.17% | 10.47B | |
+1.80% | 8.97B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Transcript : Intra-Cellular Therapies, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 07